RyanWidauRyan Widau41.78927490000000-87.6012500000000018Widau, RyanPostdoctoral Scholarplugins:TwitterTwitterprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonOsmanuddinAhmedOsmanuddin Ahmed41.7886000000000087.598699999999993682Ahmed, OsmanuddinAssociate ProfessorRadiation and Cellular OncologyMedicine-GastroenterologyAuthorship 11379729Authorship 1227127Authorship 1185047Authorship 121832230482772Ranoa DRE, Widau RC, Mallon S, Parekh AD, Nicolae CM, Huang X, Bolt MJ, Arina A, Parry R, Kron SJ, Moldovan GL, Khodarev NN, Weichselbaum RRCancer researchSTING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability. Cancer Res. 2019 04 01; 79(7):1465-1479.Cancer Res2018-11-27T00:00:002018STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability.29317191Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa KClinical lung cancerRandomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018 05; 19(3):213-220.e4.Clin Lung Cancer2017-11-21T00:00:002017Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.29853658Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau IThe oncologistRamucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist. 2018 12; 23(12):1407-e136.Oncologist2018-05-31T00:00:002018Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).28916371Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T, RANGE study investigatorsLancet (London, England)Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017 Nov 18; 390(10109):2266-2277.Lancet2017-09-12T00:00:002017Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.D008113Disorders2157310.621629Liver NeoplasmsD006528Disorders1163800.720419Carcinoma, HepatocellularAuthorship 1308971331301962Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau IThe Lancet. OncologyRamucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019 08; 20(8):1109-1123.Lancet Oncol2019-07-10T00:00:002019Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.Authorship 407301Authorship 1359071832085038Meyer T, Finn R, Kudo M, Kang Y, Yen C, Galle P, Llovet J, Assenat E, Brandi G, Motomura K, Okusaka T, Hubner R, Karwal M, Baron A, Ikeda M, Liang K, Wang C, Widau R, Schelman W, Zhu AAnnals of oncology : official journal of the European Society for Medical OncologyRamucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Ann Oncol. 2019 Jul; 30 Suppl 4:iv133.Ann Oncol2019-12-04T00:00:002019Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH).Authorship 1370071632279446Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Drove Ubreva N, Widau RC, Shinozaki K, Yoshikawa R, Zhu AXLiver international : official journal of the International Association for the Study of the LiverRamucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int. 2020 08; 40(8):2008-2020.Liver Int2020-05-06T00:00:002020Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.Authorship 463962Authorship 492731Daniel W.Golden02VmB6UQF8zMknJtY0fp/Cv/+94=Daniel W. Golden0.000000000000000.000000000000002892Golden, Daniel W.Associate ProfessorAuthorship 142353933188713Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AXLiver international : official journal of the International Association for the Study of the LiverPattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int. 2021 03; 41(3):598-607.Liver Int2020-12-05T00:00:002020Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.Authorship 1431421733392490Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AXJHEP reports : innovation in hepatologyEffect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Rep. 2021 Apr; 3(2):100215.JHEP Rep2020-11-13T00:00:002020Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.Radiology-Vascular/Interventional RadiologyAuthorship 1439641833531690Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo MBritish journal of cancerSerum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 04; 124(8):1388-1397.Br J Cancer2021-02-03T00:00:002021Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.Authorship 145027933743189Kudo M, Ikeda M, Galle PR, Yamashita T, Finn RS, Liang K, Wang C, Sakaguchi S, Abada P, Widau RC, Zhu AXHepatology research : the official journal of the Japan Society of HepatologyRamucirumab in patients with advanced hepatocellular carcinoma and elevated a-fetoprotein: Outcomes by treatment-emergent ascites. Hepatol Res. 2021 Jun; 51(6):715-721.Hepatol Res2021-05-04T00:00:002021Ramucirumab in patients with advanced hepatocellular carcinoma and elevated a-fetoprotein: Outcomes by treatment-emergent ascites.20220139Widau RC, Jin Y, Dixon SA, Wadzinski BE, Gallagher PJThe Journal of biological chemistryProtein phosphatase 2A (PP2A) holoenzymes regulate death-associated protein kinase (DAPK) in ceramide-induced anoikis. J Biol Chem. 2010 Apr 30; 285(18):13827-38.J Biol Chem2010-03-10T00:00:002010Protein phosphatase 2A (PP2A) holoenzymes regulate death-associated protein kinase (DAPK) in ceramide-induced anoikis.Authorship 1476481834173317Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Touchefeu Y, Koh SJ, Stirnimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AXLiver international : official journal of the International Association for the Study of the LiverRamucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver Int. 2021 11; 41(11):2759-2767.Liver Int2021-08-08T00:00:002021Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.22907756Widau RC, Zheng Y, Sung CY, Zelivianskaia A, Roach LE, Bachmeyer KM, Abramova T, Desgardin A, Rosner A, Cunningham JM, Skapek SXMolecular and cellular biologyp19Arf represses platelet-derived growth factor receptor ß by transcriptional and posttranscriptional mechanisms. Mol Cell Biol. 2012 Nov; 32(21):4270-82.Mol Cell Biol2012-08-20T00:00:002012p19Arf represses platelet-derived growth factor receptor ß by transcriptional and posttranscriptional mechanisms.21985982Zhang L, Widau RC, Herring BP, Gallagher PJBiochimica et biophysica actaDelta-like 1-Lysine613 regulates notch signaling. Biochim Biophys Acta. 2011 Dec; 1813(12):2036-43.Biochim Biophys Acta2011-10-02T00:00:002011Delta-like 1-Lysine613 regulates notch signaling.Authorship 1511171734721507Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AXLiver cancerRamucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer. 2021 Sep; 10(5):451-460.Liver Cancer2021-07-12T00:00:002021Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).Authorship 1533821235247922Llovet JM, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau RC, Gonzalez-Gugel E, Zhu AXClinical cancer research : an official journal of the American Association for Cancer ResearchPrognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clin Cancer Res. 2022 06 01; 28(11):2297-2305.Clin Cancer Res2022-06-01T00:00:002022Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.D020365Chemicals & Drugs20350.966541RNA HelicasesD061067Chemicals & Drugs2139290.656166Antibodies, Monoclonal, HumanizedAuthorship 1592884Authorship 15963111Authorship 1598051436190331Finn RS, Yau T, Hsu CH, De Toni EN, Goyal L, Galle PR, Qin S, Rao S, Sun F, Wang C, Widau RC, Zhu AXThe oncologistRamucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2. Oncologist. 2022 12 09; 27(12):e938-e948.Oncologist2022-12-09T00:00:002022Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.36285590Zhu AX, Lin Y, Ferry D, Widau RC, Saha AImmunotherapySurrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Immunotherapy. 2022 Nov; 14(16):1341-1351.Immunotherapy2022-10-26T00:00:002022Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.36247923Shao G, Bai Y, Yuan X, Chen X, Gu S, Gu K, Hu C, Liang H, Guo Y, Wang J, Yen CJ, Lee VH, Wang C, Widau RC, Zhang W, Liu J, Zhang Q, Qin SEClinicalMedicineRamucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study. EClinicalMedicine. 2022 Dec; 54:101679.EClinicalMedicine2022-10-06T00:00:002022Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.http://roecsg.uchicago.edu/Radiation Oncology Education Collaborative Study Group (ROECSG)d_golden@TheRealDoctorOs@SeanPitroda24434553Widau RC, Parekh AD, Ranck MC, Golden DW, Kumar KA, Sood RF, Pitroda SP, Liao Z, Huang X, Darga TE, Xu D, Huang L, Andrade J, Roizman B, Weichselbaum RR, Khodarev NNProceedings of the National Academy of Sciences of the United States of AmericaRIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E484-91.Proc Natl Acad Sci U S A2014-01-13T00:00:002014RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation.D011839Phenomena391210.950138Radiation, IonizingMedicineBSD MicrobiologyRadiation OncologyUniversity of ChicagoBernardRoizman1Wd7BaAHHaLLnnN+bUfg02fp+4Wo6r1Xc3h9eaOOFmI=Bernard Roizman41.78927490000000-87.601250000000001112Roizman, BernardEmeritus/Emerita, ProfessorArifShaikhArif Shaikh41.78927490000000-87.601250000000001196Shaikh, ArifClinical Assistant ProfessorByronBurnetteByron Burnette41.78927490000000-87.601250000000001633Burnette, ByronPostdoctoral Scholar1.062040.0166169118research areas0.2959840.043184810coauthor of21.26592.5941460similar to1122selected publicationsSamuelHellmanSamuel Hellman41.78927490000000-87.601250000000001875Hellman, SamuelEmeritus/Emerita, ProfessorRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, ProfessorRalph R.WeichselbaumxXB+DqgWEf/5hHlsaUXv9Gq0+s+oRalph R. Weichselbaum41.78927490000000-87.601250000000002521Weichselbaum, Ralph R.ProfessorBrianBudkeBrian Budke41.78927490000000-87.601250000000002603Budke, BrianPostdoctoral ScholarRobertChinRobert Chin41.78927490000000-87.60125000000000544Chin, RobertAssistant ProfessorYusukeNakamuraYusuke Nakamura41.78927490000000-87.60125000000000582Nakamura, YusukeEmeritus/Emerita, ProfessorYanZhengYan Zheng41.78927490000000-87.60125000000000842Zheng, Yantrue1true1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Postdoctoral ScholarPostdoctoral Scholartrue1Assistant ProfessorAssistant Professortrue1Postdoctoral ScholarPostdoctoral Scholartrue1Clinical Assistant ProfessorClinical Assistant Professortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Postdoctoral ScholarPostdoctoral Scholartrue1Associate ProfessorAssociate ProfessorAuthorship 693571Authorship 73033524422024Spiotto MT, Pytynia M, Liu GF, Ranck MC, Widau RJournal of oral & maxillofacial researchAnimal models to study the mutational landscape for oral cavity and oropharyngeal cancers. J Oral Maxillofac Res. 2013 Apr 01; 4(1):e1.J Oral Maxillofac Res2013-04-01T00:00:002013Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers.Chicago60637ILSeanPitrodaSean Pitroda0.000000000000000.000000000000003299Pitroda, SeanAssociate ProfessorAnjanaPillaiAnjana Pillai0.000000000000000.000000000000003399Pillai, AnjanaAssociate Professor